SCHEMBL2162369

SCHEMBL2162369

[N-]=[N+]=C(C(=O)O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.53
CES1 P23141 2/20 0.53
SRD5A2 P31213 2/20 0.52
PTPN1 P18031 2/20 0.50
NR4A1 P22736 1/20 0.46
NR4A2 P43354 1/20 0.46
NR4A3 Q92570 1/20 0.46
GSK3B P49841 2/20 0.46
CYP1A1 P04798 1/20 0.42
MAOB P27338 1/20 0.42
CYP1B1 Q16678 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
EPHX2 P34913 2/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD11B1 P28845 1/20 0.41
CYP2C8 P10632 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5171104 0.83 PSEN1 (0.51) CES2CES1SRD5A2PTPN1GSK3B
SCHEMBL5171097 0.83 PSEN1 (0.51) CES2CES1SRD5A2PTPN1GSK3B
SCHEMBL2895507 0.81 CES2 (0.53) CES2SRD5A2
SCHEMBL14638979 0.80 CES2 (0.47) CES2CES1SRD5A2PTPN1NR4A1
SCHEMBL28252458 0.79 CES2 (0.48) CES2CES1PTPN1NPC1RAB9A
SCHEMBL12398654 0.77 CES2 (0.44) CES2CES1SRD5A2PTPN1NR4A1
SCHEMBL16401498 0.76 NPSR1 (0.50) CES2CES1PTPN1GSK3BCYP1A1
SCHEMBL993397 0.76 CES1 (0.46) CES2CES1SRD5A2PTPN1MEN1
SCHEMBL28464639 0.75 ALDH1A1 (0.52) CES2CES1SRD5A2GSK3BNPC1
SCHEMBL3140047 0.75 CES2 (0.48) CES2CES1GSK3BCYP1B1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111808003-A Preparation method of thioether 甘肃农业大学 2020-10-23 CN disclosed
EP-2007724-B1 PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (GB) 2012-05-02 EP disclosed
US-7985758-B2 Piperidine derivatives for treatment of Alzheimer's disease MERCK, SHARP & DOHME LIMITED (GB) 2011-07-26 US disclosed
US-20090186919-A1 PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2009-07-23 US disclosed
EP-2007724-A1 PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE Merck Sharp & Dohme Limited (GB) 2008-12-31 EP disclosed
WO-2007116228-A1 PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186919-A1 PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE BACE1, PSEN1, PSEN2 CES2 813/4885CES1 1422/4885SRD5A2 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.